MCID: HPT073
MIFTS: 73

Hepatitis C Virus

Categories: Genetic diseases, Infectious diseases, Rare diseases, Liver diseases, Gastrointestinal diseases, Immune diseases

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 53
Hepatitis C Virus Infection, Response to Therapy of 53 28
Hepatitis C Virus, Susceptibility to 53 28
Response to Antiviral Treatment in Hepatitis C 55
Hepatitis C Virus, Response to Therapy of 53
Response to Peg/ifn-Ribavirin in Hcv 55
Hepatitis C Virus, Resistance to 53
Hcv, Susceptibility to 53
Hcv 53

Classifications:



External Ids:

OMIM 53 609532
Orphanet 55 ORPHA284102

Summaries for Hepatitis C Virus

OMIM : 53 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532)

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus infection, response to therapy of, is related to hepatitis c and hepatitis. An important gene associated with Hepatitis C Virus is IFNL3 (Interferon Lambda 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Miconazole and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and homeostasis/metabolism

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 364)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 33.7 CD81 CLDN1 CLDN6 CLEC4M GPT HM13
2 hepatitis 32.9 CD81 CLDN1 CLDN6 GPT IFNL4 PSMA7
3 hepatitis b 31.6 DDX3X GPT IFNG PIK3CA PSMA7
4 helicobacter pylori infection 30.5 EGFR HLA-DRB1 IFNG
5 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.2
6 hepatocellular carcinoma 11.6
7 fibrillary glomerulonephritis 11.1
8 immunotactoid glomerulopathy 11.1
9 immunotactoid or fibrillary glomerulopathy 11.1
10 cryoglobulinemia 10.7
11 cryoglobulinemia, familial mixed 10.7
12 hemorrhagic fever 10.6 GPT HLA-DRB1 IFNG
13 cholangitis 10.6 CLDN1 GPT HLA-DRB1
14 berylliosis 10.6 HLA-DRB1 IFNG
15 recurrent respiratory papillomatosis 10.6 EGFR HLA-DRB1
16 tumor suppressor gene on chromosome 11 10.6 EGFR PIK3CA
17 chronic beryllium disease 10.5 HLA-DRB1 IFNG
18 liver disease 10.5
19 glomerulonephritis 10.5
20 fibrosis of extraocular muscles, congenital, 1 10.5
21 ethmoid sinus cancer 10.5 EGFR PIK3CA
22 lymphoma 10.5
23 membranoproliferative glomerulonephritis 10.4
24 noonan syndrome 3 10.4
25 porphyria cutanea tarda 10.4
26 porphyria 10.4
27 ethmoid sinus adenocarcinoma 10.4 EGFR PIK3CA
28 vasculitis 10.4
29 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
30 liver cirrhosis 10.4
31 lichen planus 10.3
32 blood group, i system 10.3
33 cystic lymphangioma 10.3 IFNG PIK3CA
34 oral lichen planus 10.3
35 b-cell lymphomas 10.2
36 type ii mixed cryoglobulinemia 10.2
37 arthritis 10.1
38 thyroiditis 10.1
39 membranous nephropathy 10.1
40 cholangiocarcinoma 10.1
41 leukemia 10.1
42 thalassemia 10.1
43 polyarteritis nodosa, childhood-onset 10.1
44 thrombocytopenia 10.1
45 hepatitis d 10.1
46 kidney disease 10.1
47 hemophilia 10.1
48 alcoholic hepatitis 10.0
49 chronic kidney failure 10.0
50 diffuse large b-cell lymphoma 10.0

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM:

609532

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.1 CD81 CLDN1 DDX3X GPT HM13 PNKD

MGI Mouse Phenotypes related to Hepatitis C Virus:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 ATG5 CCR5 CD81 CLDN1 CLEC4M DDX3X
2 immune system MP:0005387 10.06 ATG5 CCR5 CD81 CLEC4M EGFR HM13
3 liver/biliary system MP:0005370 9.8 PTPRC SCARB1 ATG5 CCR5 EGFR HM13
4 muscle MP:0005369 9.76 SCARB1 ATG5 CCR5 DDX3X EGFR HM13
5 nervous system MP:0003631 9.7 ATG5 CCR5 CD81 DDX3X EGFR HM13
6 no phenotypic analysis MP:0003012 9.17 CCR5 CLDN6 EGFR IFNG PIK3CA PNKD

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 571)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
3
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
4
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
9
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 215647-85-1, 99210-65-8
10
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
11
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
12
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
13
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 143491-57-0 60877
14
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
15
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
16
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
17
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1256388-51-8 67505836
18
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1190307-88-0 45375808
19
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
20
Insulin Glargine Approved Phase 4 160337-95-1
21
Insulin-glulisine Approved Phase 4 207748-29-6
22
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
23
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
24
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 1
25
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
26
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
27
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
28
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
30
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 154598-52-4 64139
31
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 134678-17-4 60825
32
Zidovudine Approved Phase 4,Phase 1,Phase 2 30516-87-1 35370
33
Interferon alfacon-1 Approved, Investigational Phase 4,Phase 3,Phase 2 118390-30-0 9554198
34
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
35
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
36
Heroin Approved, Illicit, Investigational Phase 4,Phase 3 561-27-3 5462328
37
Nevirapine Approved Phase 4 129618-40-2 4463
38
Rifaximin Approved, Investigational Phase 4,Phase 2 80621-81-4 6436173
39
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
40
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
41
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
42
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
43
Daclizumab Approved, Investigational Phase 4 152923-56-3
44
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
45
Losartan Approved Phase 4 114798-26-4 3961
46
Iron Approved Phase 4,Phase 2 7439-89-6 23925
47
Nelfinavir Approved Phase 4 159989-64-7 64143
48
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
49
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
50
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 2180)

# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
3 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
4 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
5 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
6 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
7 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
8 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
9 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
10 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
11 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
12 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
13 Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
14 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
15 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
16 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
17 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
18 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
19 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
20 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
21 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
22 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
23 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
24 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
25 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
26 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
27 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
28 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
29 Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel) Unknown status NCT01230931 Phase 4
30 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
31 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
32 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
33 A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir Completed NCT02103699 Phase 4 No intervention
34 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
35 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
36 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
37 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
38 Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
39 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
40 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4 Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
41 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
42 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4 cyclosporin (Neoral);tacrolimus (Prograf)
43 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4 Pegylated interferon alfa-2a + Ribavirin
44 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
45 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C Completed NCT00917358 Phase 4 Pegylated interferon alfa-2a
46 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
47 Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy Completed NCT01120795 Phase 4 Pegylated interferon and ribavirin;Pegylated interferon and ribavirin
48 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. Completed NCT00545233 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin [Copegus];Pioglitazone
49 PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. Completed NCT00087633 Phase 4 peginterferon alfa-2a [Pegasys];Copegus
50 A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C Completed NCT01675427 Phase 4

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

# Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 28 CCR5 IFNG IFNL3 PTPRC
2 Hepatitis C Virus Infection, Response to Therapy of 28

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

38
Liver, Testes, Kidney, T Cells, B Cells, Heart, Bone

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 3674)
# Title Authors Year
1
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
2
Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. ( 29437963 )
2018
3
Plant-derived antivirals against hepatitis c virus infection. ( 29439720 )
2018
4
Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. ( 29438397 )
2018
5
The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. ( 29411135 )
2018
6
Hepatitis C virus infection and risk of osteoporotic fracture: A systematic review and meta-analysis. ( 29322660 )
2018
7
Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. ( 29446443 )
2018
8
Notes from the Field: Underreporting of Maternal Hepatitis C Virus Infection Status and the Need for Infant Testing - Oregon, 2015. ( 29447143 )
2018
9
The next wave of hepatitis C virus: The epidemic of intravenous drug use. ( 29427493 )
2018
10
Atypical generalized morphea-like scleroderma occurring in a patient exposed to organic solvents and having chronic hepatitis C virus infection. ( 29451196 )
2018
11
Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model. ( 29437969 )
2018
12
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. ( 29438195 )
2018
13
Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. ( 29435197 )
2018
14
Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. ( 29445495 )
2018
15
Hepatitis C virus core+1/ARFP modulates Cyclin D1/pRb pathway and promotes carcinogenesis. ( 29444947 )
2018
16
Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. ( 29429421 )
2018
17
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. ( 29235977 )
2018
18
Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma. ( 29416725 )
2018
19
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. ( 29439971 )
2018
20
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. ( 29318374 )
2018
21
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan. ( 29429413 )
2018
22
Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. ( 29443378 )
2018
23
Spontaneous bacterial peritonitis due to Helicobacter pylori in a cirrhotic patient with human immunodeficiency virus and hepatitis C virus coinfection. ( 29429754 )
2018
24
Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. ( 28521955 )
2017
25
Hepatitis C virus infection propagates through interactions between Syndecan-1 and CD81 and impacts the hepatocyte glycocalyx. ( 27930836 )
2017
26
Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults. ( 28081037 )
2017
27
T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection. ( 27809352 )
2017
28
Hepatitis C virus-associated cryoglobulinemia with membrano-proliferative glomerulonephritis treated with prednisolone and interferon: A case report. ( 28810602 )
2017
29
Community-based molecular epidemiology study of hepatitis C virus infection in injection drug users. ( 28943522 )
2017
30
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. ( 28535298 )
2017
31
Acquired hemophilia A resolution in a hepatitis C virus/human immunodeficiency virus-coinfected patient with cure of hepatitis C by direct-acting antiviral agents. ( 28960371 )
2017
32
Single-Center Experience in Pre-transplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA). ( 28935852 )
2017
33
Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. ( 28533673 )
2017
34
Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma. ( 29430221 )
2017
35
Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells. ( 28935193 )
2017
36
Hepatitis C Virus-Associated Aortitis Caused by Type I Cryoglobulins. ( 29090238 )
2017
37
Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. ( 28512091 )
2017
38
Hepatitis C virus lipoviroparticles (HCV-LVP) assemble in the endoplasmic reticulum (ER) and bud off from the ER to Golgi in COPII vesicles. ( 28515296 )
2017
39
Lurking epidemic of hepatitis C virus infection in Iran: A call to action. ( 28932350 )
2017
40
Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda. ( 28369802 )
2017
41
Primary Care Perspectives on Hepatitis C Virus Screening, Diagnosis and Linking Patients to Appropriate Care. ( 28087291 )
2017
42
A preliminary investigation on single nucleotide polymorphism rs2287622 of bile salt export pump gene in patients with chronic hepatitis C virus infection in Hunan, China. ( 28292275 )
2017
43
Genotype Distribution and Molecular Epidemiology of Hepatitis C Virus in Guangzhou, China: Predominance of Genotype 1b and Increasing Incidence of Genotype 6a. ( 28950254 )
2017
44
Comparison of Abbott RealTime genotype II, GeneMatrix restriction fragment mass polymorphism, and Sysmex HISCL HCV Gr assays for hepatitis C virus genotyping. ( 28076298 )
2017
45
Clinical development of hepatitis C virus host-targeting agents. ( 28087068 )
2017
46
Corrigendum to: Hepatitis C virus (HCV) infection of peripheral blood mononuclear cells in patients with type II cryoglobulinemia. Hum Immunol. 2013;74(12):1559-62. ( 29173492 )
2017
47
Prevalence and correlates of hepatitis C virus-associated inflammatory arthritis in a population-based cohort. ( 28532574 )
2017
48
Pityriasis rosea in a patient with retrovirus infection and a history of syphilis and positive results of infection with hepatitis A virus, hepatitis B virus and hepatitis C virus. ( 28670260 )
2017
49
Hepatitis C virus down-regulates SERPINE1/PAI-1 expression to facilitate its replication. ( 28857040 )
2017
50
Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. ( 28163062 )
2017

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPRC PTPRC, 77C-G single nucleotide variant risk factor

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 chemokine (C-X-C motif) ligand 10 Liver + 4.26 0.000
2 CXCL11 chemokine (C-X-C motif) ligand 11 Liver + 3.57 0.000
3 LOC553137 uncharacterized LOC553137 Liver - 3.21 0.000
4 CXCL9 chemokine (C-X-C motif) ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.1 CCR5 EGFR HLA-DRB1 HM13 PTPRC SCARB1

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.73 ATG5 CLEC4M DDX3X IFNL3 IFNL4 PIK3CA
2 defense response to virus GO:0051607 9.67 IFNG IFNL3 IFNL4 PTPRC
3 viral process GO:0016032 9.65 CCR5 CD81 CLDN1 CLDN6 CLEC4M DDX3X
4 T cell receptor signaling pathway GO:0050852 9.62 HLA-DRB1 PIK3CA PSMA7 PTPRC
5 cell surface receptor signaling pathway GO:0007166 9.55 CCR5 CD81 EGFR IFNG PTPRC
6 positive regulation of immune response GO:0050778 9.43 IFNL3 IFNL4
7 regulation of T cell activation GO:0050863 9.4 IFNL3 IFNL4
8 viral entry into host cell GO:0046718 9.17 CD81 CLDN1 CLDN6 CLEC4M EGFR HLA-DRB1

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.23 CCR5 CD81 CLDN1 CLDN6 CLEC4M EGFR
2 MHC class II protein complex binding GO:0023026 8.96 CD81 HLA-DRB1

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....